Abivax SA

ABVX

Healthcare|Biotechnology|France

$139.90

-0.87 (-0.62%)

Tangible Book

$5.81

Earnings Power

$7.00

Clinical Trials (23)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT05535946 ABTECT - Maintenance	Ulcerative Colitis	P3	Active	1,116	RCT, Double-blind	ABX464, Placebo
NCT03897543 ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma	Carcinoma, Hepatocellular	P1P2	Recruiting	48	Open-label	ABX196
NCT05177835 Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis	Ulcerative Colitis	P2	Active	203	Open-label	ABX464
NCT06456593 Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease	Moderately to Severely Active Crohn Disease	P2	Recruiting	212	RCT, Double-blind	Obefazimod
NCT07453784 Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation	Healthy	P1	Recruiting	44	RCT, Open-label	Obefazimod 50 mg Capsule, Obefazimod Minitablet 50 mg
NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Ulcerative Colitis	P3	Completed	639	RCT, Double-blind	ABX464, Placebo
NCT02249988 Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B	Chronic Hepatitis B	P2P3	Completed	261	RCT, Open-label	ABX203 therapeutic Hepatitis B vaccine treatment arm
NCT04393038 ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19	COVID-19	P2P3	Terminated	509	RCT, Double-blind	ABX464, Placebo
NCT03905109 Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients	Crohn Disease	P2P3	Withdrawn	—	RCT, Double-blind	ABX464, Placebo
NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Ulcerative Colitis	P3	Completed	636	RCT, Double-blind	ABX464, Placebo
NCT03093259 ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis	Ulcerative Colitis	P2	Completed	32	RCT, Double-blind	ABX464, Placebo oral capsule
NCT03813199 Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	P2	Completed	60	RCT, Double-blind	ABX464 50mg, Matching Placebo, ABX464 100mg, Methotrexate
NCT03368118 Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis	Ulcerative Colitis	P2	Completed	22	Open-label	ABX464
NCT04023396 Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis	Ulcerative Colitis	P2	Completed	217	Open-label	ABX464
NCT04049448 Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	P2	Completed	40	Open-label	ABX464
NCT02735863 ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment	HIV Infection	P2	Completed	30	RCT, Double-blind	ABX464, Placebo
NCT03760003 Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis	Ulcerative Colitis	P2	Completed	355	RCT, Double-blind	ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, Placebo
NCT02452242 Safety, PK and PD Study of ABX464 in Untreated HIV Patients	Human Immunodeficiency Virus Infections	P2	Completed	70	RCT, Double-blind	ABX464
NCT02990325 A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults	HIV Infections, Health Volunteers	P1P2	Completed	36	Open-label	ABX464 150mg, ABX464 50mg, ABX464 50mg
NCT02792686 ABX464 First in Man Study	Healthy Volunteers	P1	Completed	24	Open-label	ABX464
NCT02731885 Food Effect on Pharmacokinetic Parameters of ABX464	Healthy Volunteers	P1	Completed	48	RCT, Open-label	ABX464 Single dose, ABX464 Repeated dose
NCT05032560 Safety and Pharmacokinetics Study in Healthy Japanese Volunteers	Healthy Volunteers	P1	Completed	48	RCT, Double-blind	ABX464, Placebo
NCT05121714 Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464	Healthy	P1	Completed	59	Open-label	Caffeine, ABX464, Fluvoxamine